Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 19, 2026, 4:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Sustiva Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

CYP2B6 Genetics and Drug Interactions in Healthy Volunteers

NCT02401256
View directory record Official record
Conditions
Healthy
Interventions
Efavirenz, Bupropion, Rosuvastatin, Montelukast
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 49 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 10, 2017 · Synced Sep 19, 2026, 4:46 AM EDT
Completed Phase 2 Interventional

Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected Patients

NCT00002234
View directory record Official record
Conditions
HIV Infections
Interventions
Efavirenz, Adefovir dipivoxil, Lamivudine, Didanosine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
13 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
5
States / cities
Beverly Hills, California • Denver, Colorado • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 19, 2026, 4:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Interactions Between Antiretroviral Agents and Antimalarial Drug Combinations

NCT00697892
View directory record Official record
Conditions
HIV Infections, Malaria
Interventions
lopinavir/ritonavir, efavirenz, artemether/lumefantrine
Drug
Lead sponsor
Fran Aweeka
Other
Eligibility
21 Years to 60 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2013 · Synced Sep 19, 2026, 4:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Determine the Effect of Efavirenz on the ECG QTcF Interval in Healthy Subjects

NCT02164812
View directory record Official record
Conditions
HIV/AIDS
Interventions
Moxifloxacin, Placebo, Efavirenz
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 49 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 6, 2015 · Synced Sep 19, 2026, 4:46 AM EDT
Completed Phase 3 Interventional

A Study of Three Different Anti-HIV Drug Combinations in HIV-Infected Patients

NCT00002410
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Lamivudine, Zidovudine
Drug
Lead sponsor
Dupont Merck
Industry
Eligibility
13 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
40
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 19, 2026, 4:46 AM EDT
Completed Phase 3 Interventional

A Pilot Study of Atazanavir/Ritonavir/Efavirenz as a Nucleoside Sparing Regimen

NCT00135343
View directory record Official record
Conditions
HIV Infections
Interventions
Atazanvir/ritonavir + efavirenz
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
15
States / cities
San Francisco, California • Washington D.C., District of Columbia • Atlantis, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2011 · Synced Sep 19, 2026, 4:46 AM EDT
Not listed Phase 2Phase 3 Interventional

BREATHER (PENTA 16) Short-Cycle Therapy (SCT) (5 Days on/2 Days Off) in Young People With Chronic HIV-infection

NCT01641016
View directory record Official record
Conditions
HIV
Interventions
efavirenz
Drug
Lead sponsor
PENTA Foundation
Network
Eligibility
8 Years to 24 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 1, 2015 · Synced Sep 19, 2026, 4:46 AM EDT
Completed Phase 2 Interventional

Continued Antiretroviral Therapy With Abacavir, Amprenavir and Efavirenz

NCT00001758
View directory record Official record
Conditions
HIV Infection
Interventions
Abacavir, Amprenavir, Efavirenz
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 19, 2026, 4:46 AM EDT
Completed Phase 3 Interventional

A Study of Indinavir Taken With or Without DMP 266

NCT00002393
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Efavirenz
Drug
Lead sponsor
Dupont Merck
Industry
Eligibility
13 Years to 60 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
9
States / cities
San Francisco, California • Augusta, Georgia • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 19, 2026, 4:46 AM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetics of Efavirenz in HIV-1 Infected Subjects With Hepatic Impairment

NCT00162097
View directory record Official record
Conditions
HIV Infections, Hepatic Impairment
Interventions
efavirenz containing antiretroviral regimen
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
3
States / cities
Baltimore, Maryland • San Antonio, Texas • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 13, 2010 · Synced Sep 19, 2026, 4:46 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Effectiveness of Emtricitabine, Efavirenz, and Didanosine in HIV Infected Children Who Have Taken Few or No Anti-HIV Drugs

NCT00016718
View directory record Official record
Conditions
HIV Infections
Interventions
Didanosine (ddI), Efavirenz (EFV), Emtricitabine (FTC)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
90 Days to 21 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
16
States / cities
San Diego, California • San Francisco, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Sep 19, 2026, 4:46 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Clinical Trial of CNS-targeted HAART (CIT2)

NCT00624195
View directory record Official record
Conditions
HIV Infections
Interventions
FDA Approved Antiretroviral Therapy (see list below)
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
5
States / cities
San Diego, California • San Francisco, California • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2014 · Synced Sep 19, 2026, 4:46 AM EDT
Not listed Phase 4 Interventional

Effectiveness and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) in HIV Patients Who Have Never Received Treatment

NCT00005017
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, Abacavir sulfate, Amprenavir, Efavirenz, Lamivudine, Stavudine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 19, 2026, 4:46 AM EDT
Completed Phase 4 Interventional

A Study of the Safety and Effectiveness of Combination Anti-HIV Therapy in HIV-Infected Adults

NCT00004585
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate, Lamivudine and Zidovudine, Lamivudine/Zidovudine, Abacavir sulfate, Efavirenz
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
5
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Manhasset, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 19, 2026, 4:46 AM EDT
Withdrawn Not applicable Interventional

Raltegravir Activity In Lymphoid Tissues

NCT00863668
View directory record Official record
Conditions
HIV Infection, HIV Infections
Interventions
Efavirenz + Tenofovir DF/Emtricitabine, Raltegravir + Tenofovir DF/Emtricitabine, Colonoscopy with biopsies, Inguinal Lymph Node Excision
Drug · Procedure
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 17, 2015 · Synced Sep 19, 2026, 4:46 AM EDT
Completed Phase 2 Interventional

The Effectiveness of Nelfinavir and Efavirenz, Used Alone or Together, Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs

NCT00001087
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, Nelfinavir mesylate, Efavirenz, Levocarnitine, Adefovir dipivoxil, Saquinavir, Lamivudine, Stavudine, Zidovudine, Zalcitabine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
5
States / cities
Chicago, Illinois • Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 19, 2026, 4:46 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Pharmacokinetics and Pharmacodynamics of the Etonogestrel Contraceptive Implant When Co-administered With Efavirenz

NCT01980342
View directory record Official record
Conditions
Drug Interaction
Interventions
Efavirenz
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 10, 2018 · Synced Sep 19, 2026, 4:46 AM EDT
Terminated Phase 4 Interventional Results available

Switching From Efavirenz to Atazanavir/ Ritonavir in HIV-infected Subjects With Good Virologic Suppression

NCT01194856
View directory record Official record
Conditions
HIV Infection, Mitochondrial Dysfunction
Interventions
Atazanavir/ritonavir, Efavirenz
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Sep 19, 2026, 4:46 AM EDT
Completed Not applicable Interventional Results available

Pilot Study on the Effect of Adding Raltegravir +/- a Second Drug on HIV Levels in the Gut

NCT00884793
View directory record Official record
Conditions
HIV Infections
Interventions
raltegravir, Study NNRTI, Study PI
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2012 · Synced Sep 19, 2026, 4:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

GSK1349572 Drug Interaction Study With Efavirenz

NCT01098526
View directory record Official record
Conditions
Infections, Human Immunodeficiency Virus and Herpesviridae
Interventions
GSK1349572, Efavirenz
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 24, 2017 · Synced Sep 19, 2026, 4:46 AM EDT
Completed Phase 2 Interventional

The Safety and Effectiveness of 1592U89 Plus 141W94 Plus DMP 266 in Patients With HIV Who Developed a Resistance to Protease Inhibitors

NCT00002213
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate, Amprenavir, Efavirenz
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
13 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
9
States / cities
Berkeley, California • Los Angeles, California • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 19, 2026, 4:46 AM EDT
Completed Phase 2 Interventional

Effectiveness of ABT-378/Ritonavir Plus Lamivudine Plus Efavirenz Plus Tenofovir DF in HIV-Infected Patients

NCT00038220
View directory record Official record
Conditions
HIV Infections
Interventions
Lopinavir/ritonavir, Efavirenz, Lamivudine, Tenofovir DF
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 26, 2006 · Synced Sep 19, 2026, 4:46 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Efavirenz Versus Rilpivirine on Vascular Function, Inflammation, and Oxidative Stress

NCT01585038
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Efavirenz, Rilpivirine
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 13, 2015 · Synced Sep 19, 2026, 4:46 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Determine the Effects of Gene Differences and Voriconazole on Enzyme CYP2B6 Activity in the Liver in Healthy Volunteers

NCT01104376
View directory record Official record
Conditions
Efavirenz, Metabolism and Pharmacokinetics Changes
Interventions
Efavirenz, voriconazole
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 55 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 16, 2014 · Synced Sep 19, 2026, 4:46 AM EDT